Long-range PCR and next-generation sequencing of BRCA1 and BRCA2 in breast cancer.

Individuals and families carrying mutations in BRCA1 and BRCA2 (BRCA1/2) have a markedly elevated risk of developing breast and ovarian cancers. The first-generation of BRCA1/2 mutation analysis targeted only the coding exons and has implicated protein-truncating mutations (indel, nonsense) in BRCA1/2 inactivation. Recently, heritable breast cancers have also been attributed to other exonic mutations (missense, silent) and mutations in introns and untranslated regions. However, analysis of these alterations has been prohibitively laborious and cost intensive, and the proportion of cases carrying mutations in unscreened regions of BRCA1/2 and other predisposition genes is unknown. We have developed and validated a next-generation sequencing (NGS) approach for BRCA1/2 mutation analysis by applying long-range PCR and deep sequencing. Genomic DNA from familial breast cancer patients (N = 12) were screened and NGS successfully identified all 19 distinct (51 total) BRCA1 and 35 distinct (63 total) BRCA2 sequence alterations detectable by the Sanger sequencing, with no false-negative or positive results. In addition, we report the robust detection of variants from introns and untranslated regions. These results illustrate that NGS can provide comprehensive genetic information more quickly, accurately, and at a lower cost than conventional approaches, and we propose NGS to be a more effective method for BRCA1/2 mutational analysis. Advances in NGS will play an important role in enabling molecular diagnostics and personalized treatment of breast and ovarian cancers.

[1]  A. Tan,et al.  Iniparib, a PARP1 inhibitor for the potential treatment of cancer, including triple-negative breast cancer. , 2010, IDrugs : the investigational drugs journal.

[2]  M. Chee,et al.  Microarray-based multicycle-enrichment of genomic subsets for targeted next-generation sequencing. , 2009, Genome research.

[3]  C. Schroeder,et al.  High-throughput resequencing in the diagnosis of BRCA1/2 mutations using oligonucleotide resequencing microarrays , 2010, Breast Cancer Research and Treatment.

[4]  J. Hopper,et al.  Mutation deep within an intron of MSH2 causes Lynch syndrome , 2011, Familial Cancer.

[5]  Xiaowei Chen,et al.  Intronic alterations in BRCA1 and BRCA2: effect on mRNA splicing fidelity and expression , 2006, Human mutation.

[6]  Phillip A Sharp,et al.  Predictive Identification of Exonic Splicing Enhancers in Human Genes , 2002, Science.

[7]  A. Whittemore,et al.  Comparison of DNA‐ and RNA‐Based Methods for Detection of Truncating BRCA1 Mutations , 2002, Human mutation.

[8]  J. Hellemans,et al.  Massive parallel amplicon sequencing of the breast cancer genes BRCA1 and BRCA2: opportunities, challenges, and limitations , 2011, Human mutation.

[9]  P. Ellis,et al.  PARP inhibitors in BRCA1-/BRCA2-associated and triple-negative breast cancers. , 2010, Future oncology.

[10]  Chia-Hung Liu,et al.  FASTSNP: an always up-to-date and extendable service for SNP function analysis and prioritization , 2006, Nucleic Acids Res..

[11]  Emily H Turner,et al.  Target-enrichment strategies for next-generation sequencing , 2010, Nature Methods.

[12]  D. Bentley,et al.  Identification of the breast cancer susceptibility gene BRCA2 , 1995, Nature.

[13]  Shih-Hua Lin,et al.  Recurrent deep intronic mutations in the SLC12A3 gene responsible for Gitelman's syndrome. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[14]  S. Ying,et al.  Intron-mediated RNA interference and microRNA biogenesis. , 2009, Methods in molecular biology.

[15]  D. Baralle,et al.  Splicing in action: assessing disease causing sequence changes , 2005, Journal of Medical Genetics.

[16]  T. Mok,et al.  PARP inhibition in BRCA-mutated breast and ovarian cancers , 2010, The Lancet.

[17]  E. Bertini,et al.  Identification of a deep intronic mutation in the COL6A2 gene by a novel custom oligonucleotide CGH array designed to explore allelic and genetic heterogeneity in collagen VI-related myopathies , 2010, BMC Medical Genetics.

[18]  T. Walsh,et al.  Detection of inherited mutations for breast and ovarian cancer using genomic capture and massively parallel sequencing , 2010, Proceedings of the National Academy of Sciences.

[19]  L. D. Schroeder,et al.  The Deep Intronic c.903+469T>C Mutation in the MTRR Gene Creates an SF2/ASF Binding Exonic Splicing Enhancer, Which Leads to Pseudoexon Activation and Causes the cblE Type of Homocystinuria , 2010, Human mutation.

[20]  R. Tuma.  PARP inhibitors: will the new class of drugs match the hype? , 2009, Journal of the National Cancer Institute.

[21]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[22]  A. Ratanaphan,et al.  Identification of novel intronic BRCA1 variants of uncertain significance in a Thai hereditary breast cancer family , 2011, Journal of Genetics.

[23]  Gene W. Yeo,et al.  Systematic Identification and Analysis of Exonic Splicing Silencers , 2004, Cell.

[24]  Francisco E. Baralle,et al.  Genomic variants in exons and introns: identifying the splicing spoilers , 2004, Nature Reviews Genetics.

[25]  S. Izraeli,et al.  A selective eradication of human nonhereditary breast cancer cells by phenanthridine-derived polyADP-ribose polymerase inhibitors , 2009, Breast Cancer Research.

[26]  Thomas J. White,et al.  PCR protocols: a guide to methods and applications. , 1990 .

[27]  Eamonn Sheridan,et al.  Genetic diagnosis of familial breast cancer using clonal sequencing , 2010, Human mutation.

[28]  W. Kraus,et al.  PARP inhibitors and the treatment of breast cancer: beyond BRCA1/2? , 2009, Breast Cancer Research.

[29]  C. Deng,et al.  PARP-1 inhibitors: are they the long-sought genetically specific drugs for BRCA1/2-associated breast cancers? , 2006, International journal of medical sciences.

[30]  S. Bates,et al.  PARP inhibitors in BRCA1/BRCA2 germline mutation carriers with ovarian and breast cancer , 2010, F1000 biology reports.